Publicaciones Similares
Biosimilars
It is a biological medicine that contains a
version of the active ingredient of an original biological product (reference product) whose patent has expired.
Oppotunities for orphan drugs in Latin America
There are ample opportunities for the entry of orphan drugs into the region. The size of the Latin American orphan drug market was USD 14.17 billion in 2021 and it is estimated that it will increase by 7.38% by 2026. Based on the type of drug, the biological sector dominates the orphan drug market for Latin America
Rare Diseases current situation in Latin America and the global drug market
The size of the global market in 2021 for the treatment of rare diseases was valued at USD 119.600 million it is expected to increase at a compound annual growth rate (CAGR) of 12.8% between 2022 and 2030.
Consequences of the IRA for the pharma sector
Navigating Pharma’s Evolution: Dive into the consequences of the Inflation Reduction Act 2022. From drug refunds to taxes, Medicare changes, and R&D impacts, the industry is transforming. Stay competitive with our tailored resource solutions. Contact us to thrive amidst evolving pharmaceutical dynamics.
Biosimilars in Peru
In Peru, it is necessary to implement criteria regarding the nomenclature of biosimilar medicines and the use of identifiers that allow them to be distinguished from the innovative medicine.
Biosimilars in Brazil
Brazil has designed a set of measures to increase investment in biopharmaceutical research and is promoting the production of national biological drugs.